Effects of febrile temperature on adenoviral infection and replication: implications for viral therapy of cancer
/in Hyperthermia, International Publications, Newcastle Disease Virus /von 2005-01-01 / J. Virol. 2005 Jan;79(1):581-91Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells
/in International Publications, Newcastle Disease Virus /von 2004-11-01 / Cancer Res. 2004 Nov;64(21):8057-61Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory
/in International Publications, Newcastle Disease Virus /von 2004-10-30 / Cancer Immunol. Immunother. 2005 Jun;54(6):587-98Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit
/in Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease Virus /von 2004-09-27 / J. Clin. Oncol. 2004 Nov;22(21):4272-81High cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules
/in International Publications, Newcastle Disease Virus /von 2004-08-01 / Int. J. Oncol. 2004 Aug;25(2):293-302MTH-68/H oncolytic viral treatment in human high-grade gliomas
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2004-03-01 / J. Neurooncol. 2004 Mar-Apr;67(1-2):83-93Importance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus
/in International Publications, Newcastle Disease Virus /von 2004-03-01 / Int. J. Oncol. 2004 Mar;24(3):623-34Overview of phase I studies of intravenous administration of PV701, an oncolytic virus
/in International Publications, Newcastle Disease Virus /von 2003-12-01 / Curr. Opin. Mol. Ther. 2003 Dec;5(6):618-24Recombinant Newcastle disease virus as a vaccine vector
/in International Publications, Newcastle Disease Virus /von 2003-06-01 / Poult. Sci. 2003 Jun;82(6):899-906IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution